A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10-1082 promoter genotype as predictor of disease progression

Journal of Translational Medicine

Volumn 6, Issue , 2008, Pages

  von Euw, Erika M ^a,b   Barrio, María M ^a   Furman, David ^a   Levy, Estrella M ^a   Bianchini, Michele ^a   Peguillet, Isabelle ^c   Lantz, Olivier ^c   Vellice, Alejandra ^d   Kohan, Abraham ^d   Chacón, Matías ^d   Yee, Cassian ^e   Wainstok, Rosa ^f   Mordoh, José ^a,b,d  

^a Centro de Investigaciones Oncologicas FUCA   (Argentina)

^b FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^c INSTITUT CURIE   (France)

^d INSTITUTO ALEXANDER FLEMING   (Argentina)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL VACCINE; DEXTRAN; FLUORESCEIN ISOTHIOCYANATE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MELAN A; MELANOMA ANTIGEN; TETRAMER; CANCER VACCINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADOLESCENT; ADULT; ANOREXIA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; ASTHENIA; CANCER STAGING; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL DEATH; CELL MATURATION; CELL MIGRATION; CELL STIMULATION; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; CYTOKINE PRODUCTION; DENDRITIC CELL; DIARRHEA; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOCYTOSIS; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; FOLLOW UP; GAMMA RADIATION; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VITRO STUDY; INJECTION SITE REACTION; LEUKAPHERESIS; LIVER DYSFUNCTION; LYMPH NODE DISSECTION; LYMPHOCYTE PROLIFERATION; MALE; MELANOMA; MELANOMA CELL; MONOCYTE; MYALGIA; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; PROMOTER REGION; TREATMENT OUTCOME; TUMOR IMMUNITY; UPREGULATION; VOMITING; AUTOTRANSPLANTATION; DELAYED HYPERSENSITIVITY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; NECROSIS; PATHOLOGY; PATIENT SELECTION; PREDICTION AND FORECASTING; TRANSPLANTATION;

ADOLESCENT; ADULT; APOPTOSIS; CANCER VACCINES; DENDRITIC CELLS; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; HYPERSENSITIVITY, DELAYED; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; NECROSIS; NEOPLASM STAGING; PATIENT SELECTION; PHAGOCYTOSIS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS (GENETICS); TRANSPLANTATION, AUTOLOGOUS;

EID: 40749136181     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-6-6     Document Type: Article

References (58)

1. Greenlee RT Murray T Bolden S Wingo PA Cancer statistics, 2000 CA Cancer J Clin 2000, 50(1):7-33. 10735013
2. Kirkwood JM Manola J Ibrahim J Sondak V Ernstoff MS Rao U Eastern Cooperative Oncology Group A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma Clin Cancer Res 2004, 10:1670-1677. 10.1158/ 1078-0432.CCR-1103-3 15014018
3. Koebel CM Vermi W Swann JB Zerafa N Rodig SJ Old LJ Smyth MJ Schreiber RD Adaptive immunity maintains occult cancer in an equilibrium state Nature 2007, 6; 450(7171):903-7. 10.1038/nature06309
4. Smyth MJ Dunn GP Schreiber RD Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity Adv Immunol 2006, 90:1-50. 10.1016/ S0065-2776(06)90001-7 16730260
5. Schuler G Steinman RM Dendritic cells as adjuvants for immune-mediated resistance to tumors J Exp Med 1997, 186:1183-7. 10.1084/jem.186.8.1183 9379142
6. Banchereau J Steinman RM Dendritic cells and the control of immunity Nature 1998, 392:245-52. 10.1038/32588 9521319
7. Kawakami Y Eliyahu S Delgado CH Robbins PF Sakaguchi K Appella E Yannelli JR Adema GJ Miki T Rosenberg SA Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection Proc Natl Acad Sci USA 1994, 91:6458-62. 44221 8022805 10.1073/pnas.91.14.6458
8. Kawakami Y Eliyahu S Jennings C Sakaguchi K Kang X Southwood S Robbins PF Sette A Appella E Rosenberg SA Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression J Immunol 1995, 154:3961-8. 7706734
9. Brasseur F Rimoldi D Liénard D Lethé B Carrel S Arienti F Suter L Vanwijck R Bourlond A Humblet Y Vacca A Conese M Lahaye T Degiovanni G Deraemaecker R Beauduin M Sastre X Salamon E Dréno B Jäger E Knuth A Chevreau C Suciu S Lachapelle J-M Pouillart P Parmiani G Lejeune F Cerottini J-C Boon T Marchand M Expression of MAGE genes in primary and metastatic cutaneous melanoma Int J Cancer 1995, 63:375-80. 10.1002/ijc.2910630313 7591235
10. Brichard V Van Pel A Wolfel T Wolfel C De Plaen E Lethe B Coulie P Boon T The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas J Exp Med 1993, 178:489-95. 10.1084/jem.178.2.489 8340755
11. Wang RF Appella E Kawakami Y Kang X Rosenberg SA Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes J Exp Med 1996, 184:2207-16. 10.1084/jem.184.6.2207 8976176
12. Cheresh DA Harper JR Schulz G Reisfeld RA Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells Proc Natl Acad Sci USA 1984, 81:5767-71. 10.1073/ pnas.81.18.5767 6385004 391792
13. Valmori D Dutoit V Lienard D Rimoldi D Pittet MJ Champagne P Ellefsen K Sahin U Speiser D Lejeune F Cerottini JC Romero P Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients Cancer Res 2000, 60:4499-506. 10969798
14. Schadendorf D Ugurel S Schuler-Thurner B Nestle FO Enk A Bröcker EB Grabbe S Rittgen W Edler L Sucker A Zimpfer-Rechner C Berger T Kamarashev J Burg G Jonuleit H Tüttenberg A Becker JC Keikavoussi P Kämpgen E Schuler G DC study group of the DeCOG Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DC study group of the DeCOG Ann Oncol 2006, 17(4):563-70. 10.1093/annonc/mdj138 16418308
15. Salcedo M Bercovici N Taylor R Vereecken P Massicard S Duriau D Vernel-Pauillac F Boyer A Baron-Bodo V Mallard E Bartholeyns J Goxe B Latour N Leroy S Prigent D Martiat P Sales F Laporte M Bruyns C Romet-Lemonne JL Abastado JP Lehmann F Velu T Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate Cancer Immunol Immunother 2005, 55(7):819-29. 10.1007/ s00262-005-0078-6 16187085
16. Palucka AK Ueno H Connolly J Kerneis-Norvell F Blanck JP Johnston DA Fay J Banchereau J Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity J Immunother 2006, 29:545-557. 10.1097/ 01.cji.0000211309.90621.8b 16971810
17. Goldszmid RS Idoyaga J Bravo AI Steinman R Mordoh J Wainstok R Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma J Immunol 2003, 171:5940-5947. 14634105
18. Blachere NE Darnell RB Albert ML Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation PLoS Biol 2005, 3:e185. 1084338 15839733 10.1371/journal.pbio.0030185
19. Chen Z Moyana T Saxena A Warrington R Jia Z Xiang J Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells Int J Cancer 2001, 93:539-548. 10.1002/ijc.1365 11477558
20. Thumann P Moc I Humrich J Berger TG Schultz ES Schuler G Jenne L Antigen loading of dendritic cells with whole tumor cel preparations J Immunol Methods 2003, 277:1-16. 10.1016/S0022-1759(03)00102-9 12799035
21. von Euw EM Barrio MM Furman D Bianchini M Levy EM Yee C Li Y Wainstok R Mordoh J Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8+ T lymphocytes J Transl Med 2007, 5:19. 1863425 17448240 10.1186/1479-5876-5-19
22. Nikolova PN Pawelec GP Mihailova SM Ivanova MI Myhailova AP Baltadjieva DN Marinova DI Ivanova SS Naumova EJ Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population Cancer Immunol Immunother 2007, 56:371-9. 10.1007/s00262-006-0193-z 16835788
23. Vuoristo MS The polymorphisms of interleukin-10 gene influence the prognosis of patients with advanced melanoma Cancer Genet Cytogenet 2007, 176:54-7. 10.1016/j.cancergencyto.2007.03.002 17574964
24. Howell WM Rose-Zerilli MJ Cytokine gene polymorphisms, cancer susceptibility, and prognosis J Nutr 2007, 137:194S-199S. 17182825
25. Turner DM Williams DM Sankaran D Lazarus M Sinnott PJ Hutchinson IV An investigation of polymorphism in the interleukin-10 gene promoter Eur J Immunogenet 1997, 24:1-8. 9043871
26. Mocellin S Panelli MC Wang E Nagorsen D Marincola FM The dual role of IL-10 Trends Immunol 2003, 24:36-43. 10.1016/S1471-4906(02)00009-1 12495723
27. Kohno T Mizukami H Suzuki M Saga Y Takei Y Shimpo M Matsushita T Okada T Hanazono Y Kume A Sato I Ozawa K Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer Cancer Res 2003, 63:5091-4. 12941839
28. Ruegg C Hasmim M Lejeune FJ Alghisia GC Antiangiogenic peptides and proteins: From experimental tools to clinical drugs Biochimica et Biophysica Acta Reviews on Cancer 2006, 1765:155-177. 10.1016/ j.bbcan.2005.09.003
29. AW Hamburger The human tumor clonogenic assay as a model system in cell biology Inter J Cell Cloning 1987, 5:89-107.
30. Yee C Thompson JA Byrd D Riddell SR Roche P Celis E Greenberg PD Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells Proc Natl Acad Sci USA 2002, 99:16168-16173. 138583 12427970 10.1073/pnas.242600099
31. Barrio MM Tshurl de Motta P Kaplan P von Euw EM Bravo AI Chacón RD Mordoh J A Phase I Study Of An Allogeneic Cell Vaccine (Vaccimel) with GM-SF In Melanoma Patients J Immunother 2006, 29(4):444-454. 10.1097/01.cji.0000208258.79005.5f 16799340
32. Lowry OH Rosebrough NJ Farr AL Randall RJ Protein measurement with the Folin phenol reagent J Biol Chem 1951, 193:265-275. 14907713
33. Bover L Barrio MM Slavutsky I Bravo AI Quintans C Bagnati A Lema B Schiaffi J Yomha R Mordoh J Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor Breast Cancer Res and Treat 1991, 19:47-56. 10.1007/BF01975204
34. Doyle JJ Doyle JL A rapid DNA isolation procedure for small quantities of fresh leaf tissue Phytochemistry Bulletin 1987, 19:11-15.
35. Marka M Bessenyei B Zeher M Semsei I IL-10 promoter -1082 polymorphism is associated with elevated IL-10 levels in control subjects but does not explain elevated plasma IL-10 observed in Sjogren's syndrome in a Hungarian cohort Scand J Immunol 2005, 62:474-80. 10.1111/ j.1365-3083.2005.01675.x 16305644
36. Stanilova SA Miteva LD Karakolev ZT Stefanov CS Interleukin-10-1082 promoter polymorphism in association with cytokine production and sepsis susceptibility Intensive Care Med 2006, 32:260-6. 10.1007/ s00134-005-0022-4 16435103
37. Martinez-Escribano JA Moya-Quiles MR Muro M Montes-Ares O Hernandez-Caselles T Frias JF Alvarez-Lopez MR Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients Melanoma Res 2002, 12(5):465-469. 10.1097/ 00008390-200209000-00008 12394188
38. Alonso R Suarez A Castro P Lacave AJ Gutierrez C Influence of interleukin-10 genetic polymorphism on survival rates in melanoma parients with advanced disease Melanoma Res 2004, 15:53-60. 10.1097/ 00008390-200502000-00009
39. De Vries IJ Lesterhuis WJ Scharenborg NM Engelen LP Ruiter DJ Gerritsen MJ Croockewitt S Britten CM Torensma R Adema GJ Figdor CG Punt CJ Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients Clin Cancer Res 2003, 9(14):5091-5100. 14613986
40. Adams S O'Neill D Bjardwaj N Maturation matters: Importance of maturation for antitumor immunity of dendritic cell vaccines J Clin oncol 2004, 22:3834-3835. 10.1200/JCO.2004.99.019 15365084
41. Neves AR Ensina LF Anselmo LB Leite KR Buzaid AC Câmara-Lopes LH Barbuto JA Dendritic cells derived from metastatic cancer patients vaccinated with allogeneic dendritic cell-autologous tumor cell hybrids express more CD86 and induce higher levels of interferon-gamma in mixed lymphocyte reactions Cancer Immunol Immunother 2005, 54(1):61-6. 10.1007/ s00262-004-0550-8 15693140
42. Baars A Claessen AM van den Eertwegh AJ Gall HE Stam AG Meijer S Giaccone G Meijer CJ Scheper RJ Wagstaff J Vermorken JB Pinedo HM Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients Ann Oncol 2000, 11(8):965-70. 10.1023/A:1008363601515 11038032
43. Escobar A López M Serrano A Ramirez M Pérez C Aguirre A González R Alfaro J Larrondo M Fodor M Ferrada C Salazar-Onfray F Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients Clin Exp Immunol 2005, 142(3):555-568. 1809550 16297169
44. Tuettenberg A Becker C Huter E Knop J Enk AH Jonuleit H Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients Int J Cancer 2006, 118:2617-2627. 10.1002/ijc.21679 16353138
45. Rivoltini L Kawakami Y Sakaguchi K Southwood S Sette A Robbins PF Marincola FM Salgaller ML Yannelli JR Appella E Rosenberg SA Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1 J Immunol 1995, 154:2257-65. 7868898
46. Berset M Cerottini JP Guggisber D Romero P Burri F Rimoldi D Panizzon RG Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma Int J Cancer 2001, 95:73-7. 10.1002/ 1097-0215(20010120)95:1<73::AID-IJC1013>3.0.CO;2-S 11241315
47. Clemons-Miller AR Chatta GS Hutchins L Angtuaco EJ Ravaggi A Santin AD Cannon MJ Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma Clin Cancer Res 2001, 7(3 Suppl): 917s-924s. 11300492
48. Speiser DE Pittet MJ Rimoldi D Guillaume P Luescher IF Lienard D Lejeune F Cerottini JC Romero P Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells Semin Cancer Biol 2003, 13(6):461-72. 10.1016/j.semcancer.2003.09.010 15001165
49. Schaed SG Klimek VM Panageas KS Musselli CM Butterworth L Hwu WJ Livingston PO Williams L Lewis JJ Houghton AN Chapman PB T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: Randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants Clin Cancer Res 2002, 8(5):967-72. 12006508
50. Appay V Rowland-Jones SL Lessons from the study of T-cell differentiation in persistent human virus infection Semin Immunol 2004, 16(3):205-12. 10.1016/j.smim.2004.02.007 15130505
51. Goepfert PA Bansal A Edwards BH Ritter GD Jr Tellez I McPherson SA Sabbaj S Mulligan MJ A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon J Virol 2000, 74(21):10249-55. 102068 11024158 10.1128/JVI.74.21.10249-10255.2000
52. Tan LC Gudgeon N Annels NE Hansasuta P O'Callaghan CA Rowland-Jones S McMichael AJ Rickinson AB Callan MF A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers J Immunol 162(3):1827-35. 1999 Feb 1 9973448
53. Lee PP Yee C Savage PA Fong L Brockstedt D Weber JS Johnson D Swetter S Thompson J Greenberg PD Roederer M Davis MM Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients Nat Med 1999, 5(6):677-85. 10.1038/9525 10371507
54. Appay V Jandus C Voelter V Reynard S Coupland SE Rimoldi D Lienard D Guillaume P Krieg AM Cerottini JC Romero P Leyvraz S Rufer N Speiser DE New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site J Immunol 2006, 177(3):1670-8. 16849476
55. Zou W Immunosuppressive networks in the tumour environment and their therapeutic relevance Nat Rev Cancer 2005, 5(4):263-74. 10.1038/nrc1586 15776005
56. McCarron SL Edwards S Evans PR Gibbs R Dearnaley DP Dowe A Southgate C Easton DF Eeles RA Howell WM Influence of cytokine gene polymorphisms on the development of prostate cancer Cancer Res 2002, 62(12):3369-72. 12067976
57. Havranek E Howell WM Fussell HM Whelan JA Whelan MA Pandha HS An interleukin-10 promoter polymorphism may influence tumor development in renal cell carcinoma J Urol 2005, 173(3):709-12. 10.1097/ 01.ju.0000152493.86001.91 15711248
58. Howell WM Rose-Zerilli MJ Cytokine gene polymorphisms, cancer susceptibility, and prognosis J Nutr 2007, 137(1 Suppl):194S-199S. 17182825